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Methods: A phase II study was designed to collect geﬁtinib anti-tumor 
efﬁcacy information of advanced stage NSCLC patients. Eligibility 
criteria included histological or cytological proven chemonaive stage 
IIIB/IV NSCLC, measurable disease, ECOG performance status of 0-2, 
good organ functions and candidates for platinum-based chemotherapy. 
Patients were treated with 250mg geﬁtinib per day. Tumor assessments 
were performed every two months by RECIST criteria. Responding 
or stable patients were treated until progression. To avoid bias in the 
objective response assessment, tumor samples were collected and 
tested for EGFR mutation when most patients were progressed on the 
treatment. Therefore, investigators were blinded to the tumor EGFR 
mutational status results when tumor responses were assessed. A 
radiologist independently reviewed all scans of the responding patients. 
Simon’s two-stage design was used to aim at a response rate more than 
20%. A total of 106 patients were planned. 
Results: There were 38 men and 68 women. Median age was 66.7 
(range 32.3-86.2). ECOG performance status of 0/1/2 were 0/98/8. 
There were 75 /19 / 12 patients who were nonsmokers / quitted for 1 
year / current smokers. Ninety-seven (91.5%) patients had adenocar-
cinoma histology. Investigator-assessed tumor responses are presented 
here. There were 1/58/29/14/4 patients with CR/PR/SD/PD/NE. Over-
all response rate was 55.7% (95% conﬁdence interval 46.2-65.2%) and 
disease control rate was 81.1%. EGFR gene mutation analyses were 
performed in 83 patients’ tumor samples using polymerase chain reac-
tion ampliﬁcation and direct DNA sequencing. Mutations of exons 18, 
19, 20, 21(L858R), 21(other mutations) were detected in 1/19/6/19/6 
patients. The response rate and duration of 19 patients with del 19 were 
94.7% and 11.8 months. The response rate and duration of 19 patients 
with L858R mutation were 84.2% and 11.5 months. The response prob-
abilities in patients with other mutations were low. The response rate 
for 32 patients with wild type EGFR was 28.1%. The response rate was 
65.2% in 23 patients whose EGFR mutation test were not performed. 
The response rates and durations of patients with different types of 
EGFR mutations using independent review results will be presented in 
the meeting.
Conclusions: Consistent high response rates and long response dura-
tions were observed in chemonaive good performance advanced stage 
NSCLC patients with deletion 19 or L858R mutations of EGFR in their 
tumor samples. In a good-predictive -factor enriched population, the 
response rate were still higher than or comparable to patients receiving 
chemotherapy if EGFR was tested wild type in their tumor samples or 
if mutation test can not be performed. 
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Background and Objective: Recent studies showed that somatic 
mutations in epidermal growth factor receptor(EGFR) tyrosine 
kinase(TK) domain are associated with sensitivity of non-small cell 
lung cancer(NSCLC) to TK inhibitor. This study was to analyze 
EGFR mutations in patients with NSCLC. Method: Specimens of lung 
cancer were collected from 90 consecutive NSCLC patients DNA was 
extracted from the 90 specimens.Exons19 and 21 were ampliﬁed by 
polymerase chain reaction (PCR), and sequenced and analyzed from 
both sense and antisense directions. 
Result: Somatic mutations in TK domain of EGFR in tumors were 
identiﬁed from 26 of the 90(28.9%)patients, including 16 cases(64.0%) 
of in-frame deletion in exon 19 and 9 cases(36.0%) of amino acid 
substitution in exon 21. Mutation rate was signiﬁcantly higher in 
adenocarcinoma and bronchioalveolar carcinoma than in squamous cell 
carcinoma[13/35(37.1%),and 90.0%(9/10) vs. 4/45(8.9%),P<0.0001],: 
and signiﬁcantly higher in non-smokers than in smokers[18/36(50%) 
vs 8/54(14.8%),P=0.001].: Mutation rate in women was also higher 
than in men [15/25(60%) vs 11/65(16.9%),P<0.0001]: Mutations rate 
in patients with advanced lung cancer(III, IV stage) are higher than that 
in early stage(I, II stage)[15/71(21.1%) vs 11/19(57.9%),P=0.004]: But 
there is no signiﬁcant difference in the patients of different age(<70y or 
.≥70y) [ 17/62(27.4%) vs 9/28(32.1%), P=0.534].
Conclusion: EGFR mutation rate in Chinese NSCLC patients is high. 
Adenocarcinoma (bronchioalveolar carcinoma in particularly ), non-
smoker, femal patients and patients with advanced lung cancer are four 
important factors to predict EGFR mutation.
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Gene mutations in the ATP binding site of EGFR is a well-known 
predictive factor for chemosensitivity of geﬁtinib. However, several 
additional predictive factors for geﬁtinib sensitivity were reported, i.e., 
EGFR copy number, k-ras mutation, and the other erbB family mol-
ecules. To investigate all of these predictive factors is too expensive. 
Therefore, we are now trying to evaluate chemosensitivity for geﬁtinib 
in non-small cell lung cancer, using an in vitro drug sensitivity test.
Materials and Methods: Surgically resected fresh tumor specimens 
obtained from the 22 patients with non-small cell lung cancer were 
used. There were 13 males, 9 females, ranging in age 49-84 (average 
70) years old. Sixteen patients (73%) were smokers. Sixteen adenocar-
cinoma, 4 squamous cell carcinoma, 1 lymphoepithelioma-like carci-
noma, and 1carcinoid were included. Histoculture drug response assay 
(HDRA) were used as an in vitro drug sensitivity test. HDRA technique 
was the same as we previously reported (JTCVS 133: 303-8, 2007). 
Small pieces of viable cancer tissue was placed on the collagen gel, and 
then cultured 7 days in the presence of the geﬁtinib. Concentrations of 
geﬁtinib were 5, 10, 20, and 40 μg/ml. MTT assay was used to evaluate 
the viability of cancer tissue after incubation. The inhibition rate was 
calculated by using the following formula.
Inhibition rate (%) = (1 - mean absorbance of treated tumor/weight / 
mean absorbance of control tumor /weight) x 100.
Results: Assay was successful in all specimens. Average inhibition 
rates at the concentration of 5, 10, 20, and 40 μg/ml were 8.4%, 9.8%, 
16.9%, and 45.8%, respectively. Dose-response relationship was 
observed between the inhibition rates and the geﬁtinib concentrations 
(p=0.02). In 4 patients, the inhibition rate was evaluated only at the 
concentration of 20 μg/ml (I20). 
